Moderna Inc. said its experimental coronavirus vaccine was 94.5% effective at protecting people from Covid-19 in an early look at pivotal study results, the second vaccine to hit a key milestone.
Of 95 people in the study who developed Covid-19 with symptoms so far, 90 had received a placebo and only five Moderna’s vaccine, the company said Monday. The findings move the vaccine closer to wide use, because they indicate it is effective at preventing disease that causes symptoms, including severe cases.
The…
This post first appeared on wsj.com
